首页> 外文期刊>Internal medicine journal >Migraine: diagnosis and management.
【24h】

Migraine: diagnosis and management.

机译:偏头痛:诊断和治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Migraine is the most common form of disabling primary headache and affects approximately 12% of studied Caucasian populations. Non-pharmacological management of migraine largely consists of lifestyle advice to help sufferers avoid situations in which attacks will be triggered. Preventive treatments for migraine should usually be considered on the basis of attack frequency, particularly its trend to change with time, and tract-ability to acute care. Acute care treatments for migraine can be divided into non-specific treatments (general anal-gesics, such as aspirin or non-steroidal anti--inflammatory drugs) and treatments relatively specific to migraine (ergotamine and the triptans). The triptans - sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan and frovatriptan - are potent serotonin, 5-HT1B/1D, receptor agonists which represent a major advance in the treatment of acute migraine. Chronic daily headache in association with analgesic overuse is probably the major avoidable cause of headache disability in the developed world. (Intern Med J 2003; 33: 436-442)
机译:摘要偏头痛是致残性原发性头痛的最常见形式,影响了约12%的白种人研究人群。偏头痛的非药物治疗主要包括生活方式建议,以帮助患者避免可能引发发作的情况。偏头痛的预防性治疗通常应根据发作频率考虑,尤其是其随时间变化的趋势以及对急诊的束缚能力。偏头痛的急性护理治疗可分为非特异性治疗(一般镇痛药,如阿司匹林或非甾体类抗炎药)和相对偏头痛特异性的治疗(麦角胺和曲普坦)。曲坦类药物-舒马曲坦,那拉曲普坦,利扎曲普坦,佐米曲普坦,阿莫曲普坦,依曲曲普坦和frovatriptan-是有效的5-羟色胺,5-HT1B / 1D受体激动剂,代表治疗急性偏头痛的重要进展。慢性每日头痛与镇痛药过度使用可能是发达国家中可避免的头痛残疾的主要可避免原因。 (实习生J 2003; 33:436-442)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号